Evonik Industries AG will extend the contract of Chief Executive Officer Christian Kullmann through 2030 following a unanimous decision by its supervisory board. The extension will be formally approved at the company’s Annual General Meeting on June 3.

Kullmann has led the company since May 2017 and has been with Evonik since 2003, previously serving as chief strategy officer. He has also held the role of interim chief financial officer since September.

The company also appointed Michael Rauch as chief financial officer. Rauch will assume the role on May 1.

Rauch brings experience from multiple leadership roles across the chemical and healthcare sectors. He spent 16 years at Henkel in strategy and finance positions across Germany, Sweden and China. He later served as chief financial officer and chief executive officer at CompuGroup Medical and held the CFO role at Douglas. Most recently, he served as interim CEO of Selecta AG.

Evonik said Rauch’s experience in transformation and financial management will support the company’s efforts to strengthen resilience in a volatile market environment.

Claus Rettig, who has overseen operational finance responsibilities since September, will return to his role leading the Asia-Pacific region.

Supervisory board officials cited stability and continuity as key factors behind the leadership decisions.